香港股市 已收市

QuidelOrtho Corporation (QDEL)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
42.92+0.70 (+1.66%)
市場開市。 截至 09:39AM EDT。

QuidelOrtho Corporation

9975 Summers Ridge Road
San Diego, CA 92121
United States
858 552 1100
https://www.quidelortho.com

版塊Healthcare
行業Medical Devices
全職員工7,100

高階主管

名稱頭銜支付行使價出生年份
Mr. Michael S. IskraInterim CEO, Executive VP & Chief Commercial Officer870.93k1970
Mr. Robert J. Bujarski J.D.Interim President, Executive VP & COO961.26k1969
Mr. Joseph M. Busky CPAChief Financial Officer890.63k1968
Dr. Werner Kroll Ph.D.Senior Vice President of Research & Development1.03M1957
Ms. Louise M. BrandyChief Information Officer1959
Ruben ArguetaDirector of Investor Relations
Ms. Michelle A. Hodges J.D.Senior VP, General Counsel & Corporate Secretary1.8M1963
Mr. William J. FerenczyPoint of Care Business Unit Leader1956
Ms. Tamara A. RanalliMolecular Diagnostics Business Unit Leader1973
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

公司管治

截至 2024年5月1日 止,QuidelOrtho Corporation 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中:3;董事會:2;股東權利:4;現金賠償:5。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。